Virtus Investment Advisers LLC Buys 9,028 Shares of Sarepta Therapeutics, Inc. $SRPT

Virtus Investment Advisers LLC raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 313.1% during the second quarter, HoldingsChannel reports. The institutional investor owned 11,911 shares of the biotechnology company’s stock after acquiring an additional 9,028 shares during the period. Virtus Investment Advisers LLC’s holdings in Sarepta Therapeutics were worth $204,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Ancora Advisors LLC boosted its holdings in Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 300 shares during the last quarter. Banque Transatlantique SA bought a new position in Sarepta Therapeutics during the first quarter worth $44,000. Pandora Wealth Inc. acquired a new position in Sarepta Therapeutics in the first quarter valued at $45,000. Brooklyn Investment Group lifted its holdings in Sarepta Therapeutics by 450.4% in the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 590 shares during the period. Finally, Blue Trust Inc. boosted its position in Sarepta Therapeutics by 542.3% during the second quarter. Blue Trust Inc. now owns 3,282 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 2,771 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

SRPT stock opened at $21.34 on Friday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The business has a 50-day simple moving average of $20.47 and a two-hundred day simple moving average of $22.12. The company has a market capitalization of $2.24 billion, a P/E ratio of -24.53 and a beta of 0.52. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.15). The company had revenue of $399.36 million during the quarter, compared to analysts’ expectations of $331.51 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The business’s revenue for the quarter was down 14.5% compared to the same quarter last year. During the same period last year, the company earned $0.62 earnings per share. Research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Leerink Partners lifted their price objective on Sarepta Therapeutics from $12.00 to $15.00 and gave the stock a “market perform” rating in a research report on Tuesday, September 9th. Bank of America lifted their target price on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an “underperform” rating in a report on Wednesday, October 22nd. Deutsche Bank Aktiengesellschaft increased their price target on Sarepta Therapeutics to $12.00 and gave the stock a “sell” rating in a report on Friday, August 15th. Mizuho raised shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $19.00 to $26.00 in a research report on Wednesday, November 5th. Finally, BMO Capital Markets upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a research report on Monday, September 22nd. Eight investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $33.75.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.